A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis - FIXTURE.

Trial Profile

A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis - FIXTURE.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Secukinumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms FIXTURE
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Apr 2017 Results (n=1709) of a pooled analysis from FIXTURE, FEATURE, ERASURE and JUNCTURE studies assessing the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients, published in the Advances in Therapy.
    • 08 Mar 2017 Data from this and other trials (n=1233) was used in population pharmacokinetic modelling to characterize pharmacokinetic of secukinumab in patients with psoriasis; outcomes published in the Journal of Clinical Pharmacology
    • 10 Jan 2017 Results of pooled analysis assessing effect of secukinumab treatment on patient reported health related quality of life from NCT01365455 and NCT01358578 trials, published in the Journal of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top